GlassScriptPhysician profile
Mohammad Intakhab Paracha
NPI 1255419115
$556.31
in general payments reported to CMS, 2019-2025
9 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.16 · 2020: $11.30 · 2021: $12.63 · 2022: $58.31 · 2023: $111 · 2024: $112 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $290 · Education: $89.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $289.77 |
| Education | $89.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $105.61 | 2021-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $105.13 | 2025 | Dupixent |
| Pulmonx Corporation | $99.14 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Jazz Pharmaceuticals INC. | $95.16 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $80.82 | 2023 | Lumryz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.22 | 2022 | |
| Inogen, INC. | $13.28 | 2024 | |
| Ani Pharmaceuticals, INC. | $12.65 | 2022 | |
| Sunovion Pharmaceuticals INC. | $11.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Paracha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.